Market Capitalization (Millions $) |
8 |
Shares
Outstanding (Millions) |
14 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-31 |
Cash Flow (TTM) (Millions $) |
11 |
Capital Exp. (TTM) (Millions $) |
0 |
Trevena Inc
Trevena Inc. is a pharmaceutical company located in Pennsylvania, USA that is focused on discovering, developing and commercializing therapies for serious medical conditions. The company was founded in 2008 and is publicly traded on the NASDAQ stock exchange under the symbol TRVN.
Trevena is dedicated to advancing the care of patients suffering from pain, heart failure, and other conditions that have a significant impact on overall health and quality of life. The company's innovative drug discovery platform is based on a deep understanding of chemical biology and molecular pharmacology, which enables the development of highly specific and effective therapies.
The company's lead product candidate is OLINVYKe (oliceridine), which is a new pain reliever that has been approved by the U.S. Food and Drug Administration (FDA). OLINVYK is specifically designed to address the limitations of traditional opioid analgesics by providing rapid and effective pain relief, while also minimizing common side effects such as respiratory depression, nausea, and vomiting.
In addition to OLINVYK, Trevena has a strong pipeline of product candidates that are currently in various stages of development. These include TRV027, which is being developed for the treatment of acute heart failure, and TRV250, which is being developed for the treatment of migraine headaches.
Trevena's mission is to improve the lives of patients by developing and commercializing innovative therapies that address unmet medical needs. The company is committed to maintaining the highest standards of scientific excellence and ethical conduct, and is dedicated to working collaboratively with healthcare providers, patients, and other stakeholders to achieve its goals.
Company Address: 955 Chesterbrook Boulevard, Suite 110 Chesterbrook 19087 PA
Company Phone Number: 354-8840 Stock Exchange / Ticker: NASDAQ TRVN
TRVN is expected to report next financial results on March 29, 2024. |
|
|